Payment overview · 2025
General Payments
$867.20
44 reported records · 15 companies
Healthcare provider profile · identity verified
Thomas Kizy, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ALGONAC, MI · NPI 1457637506
Verified facts
What the public records show
CMS Open Payments records show Thomas Kizy, M.D. received $867.20 in general payments during 2025 across 44 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Vraylar, Zubsolv.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Orexo US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zubsolv as an associated drug or biological on 1867 records involving 794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Zubsolv by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $206.06 | 23.8% | 10 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $123.11 | 14.2% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $114.93 | 13.2% | 6 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $77.78 | 9.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $64.97 | 7.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.92 | 6.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.17 | 5.8% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $28.58 | 3.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.62 | 3.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.83 | 2.9% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $23.48 | 2.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.70 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.23 | 2.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $17.12 | 2.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.70 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $867.20 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $169.20 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $123.11 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $93.98 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $81.67 | 5 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $77.78 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.09 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.17 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.17 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.04 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.04 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Zubsolv zubsolv |
2025 | Zubsolv | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Orexo US, Inc. Exact reporting entity; no affiliate inference |
2025 | Zubsolv open payments reported associated product |
CMS Open Payments — General Payments 1867 supporting records · 794 recipient NPIs · example record 1190507283 |
Zubsolv · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 271 | 84 |
| Lisinopril | Lisinopril | 245 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 208 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 48 |
| Alprazolam | Alprazolam | 166 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 160 | 32 |
| Simvastatin | Simvastatin | 158 | 36 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 129 | 13 |
| Metformin Hcl | Metformin Hcl | 129 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 121 | 21 |
| Gabapentin | Gabapentin | 119 | 36 |
| Omeprazole | Omeprazole | 117 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 28 |
| Ibuprofen | Ibuprofen | 98 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 30 |
| Furosemide | Furosemide | 82 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | 30 |
| Losartan Potassium | Losartan Potassium | 76 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 29 |
| Prednisone | Prednisone | 69 | 48 |
| Pregabalin | Pregabalin | 69 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 27 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 63 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 27 |
| Famotidine | Famotidine | 62 | 16 |
| Potassium Chloride | Potassium Chloride | 62 | 22 |
| Azithromycin | Azithromycin | 61 | 47 |
| Tramadol Hcl | Tramadol Hcl | 59 | 13 |
| Allopurinol | Allopurinol | 57 | 15 |
| Atenolol | Atenolol | 57 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 54 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 17 |
| Morphine Sulfate Er | Morphine Sulfate | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 15 |
| Carvedilol | Carvedilol | 45 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 42 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 36 |
| Donepezil Hcl | Donepezil Hcl | 41 | 15 |
| Sertraline Hcl | Sertraline Hcl | 40 | 16 |
| Meloxicam | Meloxicam | 39 | 15 |
| Methylprednisolone | Methylprednisolone | 39 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Eliquis | Apixaban | 36 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 11 |
| Trazodone Hcl | Trazodone Hcl | 35 | 14 |
| Belbuca | Buprenorphine Hcl | 34 | suppressed |
| Ezetimibe | Ezetimibe | 34 | 11 |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Diazepam | Diazepam | 33 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Naproxen | Naproxen | 32 | 11 |
| Ozempic | Semaglutide | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | 13 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 23 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 17 |
| Fluconazole | Fluconazole | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 15 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Indomethacin | Indomethacin | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | 13 |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 13 | 13 |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $867.20 · 44 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, BRIXADI, CAPLYTA, Dexcom G6 Transmitter, JATENZO, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SUBLOCADE, UBRELVY, VRAYLAR, Wegovy, Zubsolv | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error